TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10671828

Group type: EXPERIMENTAL
Intervention: Psychologist's structured 10-session intervention program for 20 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C-ward)
Number of subjects: 0
Study: 10167366

Group type: EXPERIMENTAL
Intervention: Prenatal smoking cessation intervention
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Taking puffs in late pregnancy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Having friends who smoke at the first prenatal visit
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Less confidence in mid‐pregnancy about maintaining nonsmoking postpartum
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Partner who smokes postpartum
Number of subjects: 127
Study: 1437861

Group type: EXPERIMENTAL
Intervention: Red low level narrow band (LLNB) light (660 nm)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Infrared LLNB light (940 nm)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (no light irradiation)
Number of subjects: 21
Study: 2867560

Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium initially and then 275 mg naproxen sodium 4-times daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: 100 mg dextropropoxyphene napsylate initially and then 100 mg dextropropoxyphene napsylate 4-times daily
Number of subjects: 68
Study: 30129062

Group type: COMPARATOR
Intervention: Bilateral lateral approach
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ventral cervical approach
Number of subjects: 8
Study: 26550959

Group type: EXPERIMENTAL
Intervention: TAU plus PMT
Number of subjects: 94

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 94
Study: 24553997

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (2,000 mg of eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Gamma-linoleic acid (borage oil containing 400 mg γ-linoleic acid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 24430037

Group type: EXPERIMENTAL
Intervention: Stalevo
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (healthy people)
Number of subjects: 73
Study: 20533764

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR) 2 g/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: Alendronate 70 mg/week
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 152
Study: 18649895

Group type: EXPERIMENTAL
Intervention: Urgent endovascular stent-graft placement
Number of subjects: 6
Study: 15867181

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/d)
Number of subjects: 20
Study: 12952834

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with 1.0 mg/kg body weight of recombinant alpha‐Gal A (agalsidase beta, Fabrazyme) for 12 months
Number of subjects: 16
Study: 10389781

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.2 microg x kg(‐1) x min(‐1) with desflurane 3.2%‐3.6%
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nonopiate with desflurane 7%‐9%
Number of subjects: 115
Study: 8877074

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2058987

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Behçet group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Behçet group and uveitis group
Number of subjects: 35
Study: 4089261

Group type: EXPERIMENTAL
Intervention: 125I permanent implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 125I permanent implant with external beam radiotherapy ('boost'-therapy)
Number of subjects: 0
Study: 30640484

Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention (EMI) that taught stress management skills for 14 days
Number of subjects: 382

Group type: COMPARATOR
Intervention: Ecological momentary assessment (EMA) with self-monitoring of stressors and mood for 14 days
Number of subjects: 382
Study: 29084101

Group type: EXPERIMENTAL
Intervention: 20-hour manualized small group cognitive-behavioral intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 35
Study: 26385162

Group type: EXPERIMENTAL
Intervention: 14-week teacher-delivered intervention focused on healthy lifestyle behaviors
Number of subjects: 618

Group type: COMPARATOR
Intervention: 14-week teacher-delivered general health curriculum (control group)
Number of subjects: 618
Study: 25248797

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weekly trainer-led group exercise sessions, instructed home exercise 3-5 times/week during 20-36 weeks of gestation, dietary counseling twice during pregnancy)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study: 22446296

Group type: COMPARATOR
Intervention: APG101 (20 mg/kg) administered as infusion over 1 hour to healthy volunteers
Number of subjects: 36

Group type: COMPARATOR
Intervention: APG101 (5 mg to 600 mg) administered intravenously to glioma patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: APG101 (400 mg) administered weekly to glioma patients
Number of subjects: 36
Study: 20942275

Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6) for 30 min
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo treated group (moxibustion at no acupoint for 30 min)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Blank group (routine labor nursing)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo treated group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Moxibustion at Sanyinjiao (SP 6) and Placebo treated group
Number of subjects: 174
Study: 16015414

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control
Number of subjects: 211
Study: 12708123

Group type: EXPERIMENTAL
Intervention: Standard exercise test (Modified Harvard Step-Test) at 2100 m and 4350 m
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard exercise test (Modified Harvard Step-Test) at 4350 m
Number of subjects: 20
Study: 10393400

Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (NAC) in combination with streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (NAC)
Number of subjects: 0
Study: 8601931

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 2459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2459
Study: 2004539

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 6599496

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion at 7.5 ng/kg/min
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (P)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Angiotensin II (AII) infusion
Number of subjects: 7
Study: 29271504

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Enhanced liver fibrosis (ELF) test
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Liver stiffness
Number of subjects: 56

Group type: COMPARATOR
Intervention: Multiparametric MRI compared to biopsy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI combined with transient elastography
Number of subjects: 56
Study: 27940182

Group type: EXPERIMENTAL
Intervention: Genomic carrier screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25559916

Group type: EXPERIMENTAL
Intervention: NOURISH-T intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) control
Number of subjects: 0
Study: 23134084

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposomes (UAL) at doses of 11, 22, 37, 56, 74, 98, and 130 mg/m(2) administered as a 4-h intravenous infusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ursolic acid liposomes (UAL)
Number of subjects: 63
Study: 21607939

Group type: EXPERIMENTAL
Intervention: Systematic full access (SFA) to the medical record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Requested access (RA) to the medical record
Number of subjects: 0
Study: 18311687

Group type: EXPERIMENTAL
Intervention: 150 mg amitriptyline
Number of subjects: 40

Group type: COMPARATOR
Intervention: 40 mg paroxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 40
Study: 16573703

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg once daily
Number of subjects: 1974

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1974
Study: 12699032

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Pretreatment gain
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sudden within-treatment gain
Number of subjects: 87
Study: 10960384

Group type: COMPARATOR
Intervention: Intrathecal morphine 0.2 mg (Group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 0.2 mg (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 0.8 mg (Group 3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine 1.6 mg (Group 4)
Number of subjects: 90
Study: 8800479

Group type: EXPERIMENTAL
Intervention: 6 h food deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 h food deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall caloric intake during the entire laboratory day
Number of subjects: 0
Study: 1629381

Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 6317737

Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg b.i.d.
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 29385952

Group type: EXPERIMENTAL
Intervention: Health and Recovery Peer (HARP) program, a self‐management program for general medical conditions led by certified peer specialists; N=198
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care; N=202
Number of subjects: 400
Study: 27026640

Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI)
Number of subjects: 6973

Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI)
Number of subjects: 6973
Study: 24115083

Group type: EXPERIMENTAL
Intervention: Intravesical 100 U onabotulinumtoxinA injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (non-diabetic patients)
Number of subjects: 48
Study: 23911756

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Angiotensin‐1 receptor blockers (ARB)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors (ACE‐I)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 2248

Group type: EXPERIMENTAL
Intervention: β‐blockers (BB)
Number of subjects: 2248
Study: 20100397

Group type: EXPERIMENTAL
Intervention: Social hand-shaking stimuli from a third-person perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inanimate effects (block arrow stimuli)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social action effects
Number of subjects: 0
Study: 18228005

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.057 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Delta‐9‐THC (0.0286 mg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Haloperidol and Delta‐9‐THC
Number of subjects: 28
Study: 16650155

Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cryosurgery or curettage and cautery
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Referral to specialist
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Doctor visits
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 164
Study: 12091491

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 1,000 mg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10995146

Group type: EXPERIMENTAL
Intervention: Heavy bupivacaine 0.5% (in dextrose 8%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine 0.5% (dextrose-free)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% in dextrose 4% (mixed)
Number of subjects: 36
Study: 7480568

Group type: EXPERIMENTAL
Intervention: Sodium loading (10 1-g tablets/day for 14 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo tablets (14 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium loading
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 36
Study: 2403006

Group type: EXPERIMENTAL
Intervention: Recombinant somatropin 0.1 mg/kg (0.27 IU/kg) three times weekly
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (10 pubertal children)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Somatropin 0.1 mg/kg (0.27 IU/kg) three times weekly (second year)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Somatropin 0.1 mg/kg (0.27 IU/kg) once-daily (second year)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Original treatment regimen (first year) continued (second year)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Changed to once-daily treatment at the same weekly dose (second year)
Number of subjects: 121
Study: 6998598

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 400 micrograms
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (both dosages)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 108
Study: 31097441

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 67
Study: 31848003

Group type: EXPERIMENTAL
Intervention: Foundations for Safety Leadership (FSL) training program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (lagged training)
Number of subjects: 20
Study: 27465633

Group type: EXPERIMENTAL
Intervention: Variable Resistance Training (VRT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 16
Study: 26178463

Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Number of subjects: 15

Group type: COMPARATOR
Intervention: NIV-PS
Number of subjects: 15
Study: 24188065

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 21070231

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 19438429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17394011

Group type: EXPERIMENTAL
Intervention: Optimised CO-rebreathing method (oCOR-method)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Former commonly used CO-rebreathing procedure
Number of subjects: 10
Study: 12946941

Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (1 kcal/min) with proximal (duodenal) distension (n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (1 kcal/min) with distal (rectal) distension (n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham distension (control group, n = 8)
Number of subjects: 24
Study: 11705299

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 9531895

Group type: EXPERIMENTAL
Intervention: Lidocaine spray applied to the cervix and cervical canal
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 300
Study: 8703650

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 2084590

Group type: EXPERIMENTAL
Intervention: Atracurium 5 mg i.v.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study: 732302

Group type: EXPERIMENTAL
Intervention: Standing position on bicycle ergometer
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sitting position on bicycle ergometer
Number of subjects: 5
Study: 30732732

Group type: EXPERIMENTAL
Intervention: Pulmonary artery denervation (PADN)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sildenafil plus sham PADN
Number of subjects: 98
Study: 28877232

Group type: EXPERIMENTAL
Intervention: Light-intensity resistance exercise (LRE) at 40% of one-repetition maximum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (HRE) at 80% of one-repetition maximum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON) - resting condition
Number of subjects: 12
Study: 25774017

Group type: EXPERIMENTAL
Intervention: Medication Review with Follow-Up (MRF) service
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Normal medication dispensing (Control Group)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Cost-Utility Analysis of MRF service
Number of subjects: 1403
Study: 23883736

Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 3 mm)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 9 mm)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MRI-derived CSF-P (OSASW at 15 mm)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CSF-P assessment based on OSASW at 9 mm and 15 mm
Number of subjects: 72
Study: 21911633

Group type: EXPERIMENTAL
Intervention: Remote physician-pharmacist team-based care
Number of subjects: 6963

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6963
Study: 19752505

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo QW
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg QW (after 24 weeks)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Placebo followed by Etanercept 50 mg QW
Number of subjects: 142
Study: 16739839

Group type: EXPERIMENTAL
Intervention: Acupoint electric stimulation using audio frequency pulse modulated wave
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 150
Study: 14507250

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (women not receiving HRT)
Number of subjects: 0
Study: 10383519

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole b.d. (LAC15 group)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole b.d. (LAC30 group)
Number of subjects: 215
Study: 8697755

Group type: EXPERIMENTAL
Intervention: Bimanual stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unimanual stimulation
Number of subjects: 32
Study: 1687852

Group type: EXPERIMENTAL
Intervention: Theophylline (625 mg orally) followed by adenosine infusion (40 micrograms kg‐1 min‐1 for 5 min, 60 micrograms kg‐1 min‐1 for 5 min, and 80 micrograms kg‐1 min‐1 for 30 min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo theophylline tablets followed by adenosine infusion
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Theophylline (625 mg orally)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Adenosine infusion only
Number of subjects: 5
Study: 6366805

Group type: EXPERIMENTAL
Intervention: 25 mg furosemide
Number of subjects: 36

Group type: COMPARATOR
Intervention: 50 mg chlorthalidone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 36
Study: 3554462

Group type: EXPERIMENTAL
Intervention: Shortened enzyme immunoassay (2 hours incubation)
Number of subjects: 4025

Group type: COMPARATOR
Intervention: Normal enzyme immunoassay (3 hours 30 minutes incubation)
Number of subjects: 4025

Group type: EXPERIMENTAL
Intervention: Shortened enzyme immunoassay
Number of subjects: 4025

Group type: COMPARATOR
Intervention: Normal enzyme immunoassay
Number of subjects: 4025
Study: 29745095

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pemetrexed plus cisplatin (PC)
Number of subjects: 53
Study: 27619104

Group type: EXPERIMENTAL
Intervention: Yoga practice (1 hour daily for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (routine medical care only)
Number of subjects: 40
Study: 23974633

Group type: EXPERIMENTAL
Intervention: Iliotibial band autograft (ITB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bone-patella-tendon-bone autograft (BPTB)
Number of subjects: 60
Study: 22499962

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin based on the weight-based dosing nomogram
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not following the standard nomogram)
Number of subjects: 25